<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00999830</url>
  </required_header>
  <id_info>
    <org_study_id>IPH2101-201</org_study_id>
    <nct_id>NCT00999830</nct_id>
    <nct_alias>NCT01937741</nct_alias>
  </id_info>
  <brief_title>Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma</brief_title>
  <acronym>REMYKIR</acronym>
  <official_title>Randomised Phase II Study Evaluating the Anti-tumour Activity, Safety and Pharmacology of Two Dose Regimens of IPH2101, a Human Monoclonal Anti-KIR Antibody, in Patients With Multiple Myeloma in Stable Partial Response After a First Line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innate Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innate Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open randomised phase II study evaluating the anti-tumour activity, safety and
      pharmacology of two dose regimens of IPH2101, a human monoclonal anti-KIR antibody, in
      patients with multiple myeloma in stable partial response after a first line therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Development of new treatments for diseases such as multiple myeloma is a focus for research.
      The research being conducted is on treatment called Anti-KIR, which activates the body's own
      cells to kill tumor cells. This is different from many other treatments where chemicals are
      given to kill tumor cells.The primary objective of the study is to evaluate the clinical
      activity of two different dose regimens (0.2 mg/kg, leading to an intermittent saturation of
      NK receptors and 2mg/kg leading to a sustained saturation of NK receptors) of IPH2101
      administered as a single agent in multiple myeloma patients who achieved, after the
      completion of any first line treatment, including conventional or high dose chemotherapies, a
      stable partial or very good partial response (PR or VGPR).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Patients Achieving a Response Based on M-protein or Free Light Chains</measure>
    <time_frame>From the start of the treatment to the End of Study and during the post study follow up during 2 years according to standard practices</time_frame>
    <description>Response was defined:
In patients with a serum M-protein &gt; 5 g/l, as a reduction of at least 25% (minor response according to European society for Blood and Marrow Transplantation (EBMT)) from baseline of serum M-protein confirmed on two consecutive determinations at 4 weeks interval;
In patients with a serum M-protein ≤ 5 g/l and ≥ 3g/l, as a negative electrophoresis
In patients with serum M-protein &lt; 3 g/l but a measurable involved serum free light chains ≥ 100 mg/l and an abnormal Free Light Chains ratio (&lt;0.26 or &gt; 1.65), as a ≥ 50 % decrease in the difference between involved and uninvolved Free Light Chains levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biological Activity of IPH2101 on Killer Immunogloblin Like Receptors (KIR) Occupancy at End of Treatment</measure>
    <time_frame>From the start up to the end of study (15 months)</time_frame>
    <description>KIR-occupancy is a relative measure of the fraction of cell surface KIR that is occupied by the IPH2101 monoclonal antibody, and hence is unavailable for binding to HLA ligands.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>from screening visit to the End of Study (at each study visit)</time_frame>
    <description>Adverse Events, Serious Adverse Events, physical examination and biological changes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>IPH 2101 0.2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One infusion of IPH2101 every 4 weeks at the dose of 0.2 mg/kg by intravenous route over 1 hour, for 4 or up to 8 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPH2101 2.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One infusion of IPH2101 every 4 weeks at the dose of 2 mg/kg by intravenous route over 1 hour, for 4 or up to 8 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPH2101</intervention_name>
    <description>One infusion of IPH2101 every 4 weeks</description>
    <arm_group_label>IPH 2101 0.2 mg/kg</arm_group_label>
    <arm_group_label>IPH2101 2.0 mg/kg</arm_group_label>
    <other_name>Fully human anti-KIR monoclonal antibody (1-7F9)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. MM which initially required a systemic therapy and received a first line treatment,
             conventional doses of chemotherapies or high dose chemotherapy and an autologous
             transplantation of hematopoietic cells, followed or not by a consolidation treatment.

          2. Residual disease considered as evaluable with:

               -  Quantifiable serum M-protein: ≥ 3 g/l, except for spike in the beta globulin
                  area. In this particular case serum M-protein is considered quantifiable if ≥
                  10g/l

               -  If serum M-protein is &lt; 3g/l, measurable involved Free Light Chains ≥ 100 mg/l
                  and an abnormal Free Light chains ratio (&lt;0.26 or &gt; 1.65)

          3. Responses which are partial (PR and VGPR) and in plateau

               -  Partial response should meet the IMWG uniform response criteria: a ≥ 50%
                  reduction from value of serum M-protein before the first line chemotherapy
                  treatment and a reduction in 24h urinary M-protein by ≥ 90% or to &lt; 200 mg /24h;

               -  Very good partial response according to the IMWG uniform response criteria with
                  90% or greater reduction in serum M-protein plus urine M-protein level &lt; 100
                  mg/24h; furthermore the M-protein should spike in the gamma globulin area;

               -  Plateau phase is defined by :

                    -  For patients with serum M-protein ≥ 3g/l: stable levels of M-protein in
                       serum during at least 2 months checked on at least 3 consecutive samples,
                       with the third evaluation performed within 4 weeks before study entry.
                       Fluctuations of ± 25 % and ± 2 g/l in Serum M-protein levels are allowed.

                    -  For Patients with serum M-protein &lt; 3g/l: stable levels Free Light Chains in
                       serum during at least 2 months checked on at least 3 consecutive samples,
                       with the third evaluation performed within 4 weeks before study entry.
                       Fluctuations of ± 25 % of involved serum Free Light Chain are allowed.

          4. ECOG performance status of 0, 1 or 2.

          5. Clinical laboratory values at screening:

               -  Calculated creatinine clearance (according to MDRD) &gt; 50 ml/min

               -  Platelet &gt; 50 x 109 /l

               -  ANC &gt; 1 x 109 /l

               -  Bilirubin levels &lt; 1.5 ULN; ALT and AST &lt; 2.5 ULN

          6. Male or female patient who accepts and is able to use recognised effective
             contraception (oral contraceptives, IUCD, barrier method of contraception in
             conjunction with spermicidal jelly) throughout the study.

          7. Signed inform consent obtained before any trial-related activities

        Exclusion Criteria:

          1. Age &lt; 18 years old or &gt; 75 years old

          2. Previous consolidation/ maintenance therapy by Imid (thalidomide, lenalidomid) or
             bortezomib within the last 2 months

          3. Treatment with chemotherapy, systemic corticosteroid within the previous 2 months

          4. Treatment with growth factors (EPO, G- or GM-CSF) within the previous 1 month

          5. Radiotherapy for bone or visceral lesion within the last 3 months

          6. Use of any investigational agent within the last 2 months

          7. Primary or associated amyloidosis

          8. Peripheral neuropathy of grade ≥ III according to the CTCAE of the NCI

          9. Abnormal cardiac status with any of the following

               1. NYHA stage III or IV congestive heart failure

               2. myocardial infarction within the previous 6 months

               3. symptomatic cardiac arrhythmia despite treatment

         10. Current active infectious disease or positive serology for HIV, HCV or positive Hbs
             Antigen

         11. History of or current auto-immune disease

         12. Serious concurrent uncontrolled medical disorder

         13. History of other malignancy for less then 5 years (apart from basal cell carcinoma of
             the skin, or in situ cervix carcinoma)

         14. History of allogenic hematopoietic cell or solid organ transplantation

         15. Pregnant or lactating women

         16. Any medical condition which is regarded by the investigator as incompatible with the
             study participation

         17. Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel ATTAL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>C.H.R.U. de Caen - Hôpital Bretonneau</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.R.U. de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2009</study_first_submitted>
  <study_first_submitted_qc>October 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2009</study_first_posted>
  <results_first_submitted>October 15, 2013</results_first_submitted>
  <results_first_submitted_qc>February 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 24, 2016</results_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited in France at the public hospital (10 actives center), from mid of November 2009 to end of October 2011.</recruitment_details>
      <pre_assignment_details>All patients enrolled in the study were analyzed. There was no screen failure during the trial conduct.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A: IPH2101 0.2mg/Kg</title>
          <description>IPH2101 Fully human anti-KIR monoclonal antibody : 0.2mg/Kg , every 4 weeks by intravenous route over 1 hour, for 4 cycles. Patients responding at 4 months will be allowed to receive an additional period of treatment of 4 monthly.</description>
        </group>
        <group group_id="P2">
          <title>Arm B: IPH2101 2mg/kg</title>
          <description>IPH2101 Fully human anti-KIR monoclonal antibody : 2mg/Kg , every 4 weeks by intravenous route over 1 hour, for 4 cycles. Patients responding at 4 months will be allowed to receive an additional period of treatment of 4 monthly.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A: IPH2101 0.2mg/Kg</title>
          <description>every 4 weeks by intravenous route over 1 hour, for 4 or up to 8 cycles.</description>
        </group>
        <group group_id="B2">
          <title>Arm B: IPH2101 2mg/kg</title>
          <description>every 4 weeks by intravenous route over 1 hour, for 4 or up to 8 cycles.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="5.6"/>
                    <measurement group_id="B2" value="55.9" spread="10.2"/>
                    <measurement group_id="B3" value="57.3" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Patients Achieving a Response Based on M-protein or Free Light Chains</title>
        <description>Response was defined:
In patients with a serum M-protein &gt; 5 g/l, as a reduction of at least 25% (minor response according to European society for Blood and Marrow Transplantation (EBMT)) from baseline of serum M-protein confirmed on two consecutive determinations at 4 weeks interval;
In patients with a serum M-protein ≤ 5 g/l and ≥ 3g/l, as a negative electrophoresis
In patients with serum M-protein &lt; 3 g/l but a measurable involved serum free light chains ≥ 100 mg/l and an abnormal Free Light Chains ratio (&lt;0.26 or &gt; 1.65), as a ≥ 50 % decrease in the difference between involved and uninvolved Free Light Chains levels.</description>
        <time_frame>From the start of the treatment to the End of Study and during the post study follow up during 2 years according to standard practices</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: IPH2101 0.2mg/Kg</title>
            <description>every 4 weeks by intravenous route over 1 hour, for 4 or up to 8 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: IPH2101 2mg/kg</title>
            <description>every 4 weeks by intravenous route over 1 hour, for 4 or up to 8 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Patients Achieving a Response Based on M-protein or Free Light Chains</title>
          <description>Response was defined:
In patients with a serum M-protein &gt; 5 g/l, as a reduction of at least 25% (minor response according to European society for Blood and Marrow Transplantation (EBMT)) from baseline of serum M-protein confirmed on two consecutive determinations at 4 weeks interval;
In patients with a serum M-protein ≤ 5 g/l and ≥ 3g/l, as a negative electrophoresis
In patients with serum M-protein &lt; 3 g/l but a measurable involved serum free light chains ≥ 100 mg/l and an abnormal Free Light Chains ratio (&lt;0.26 or &gt; 1.65), as a ≥ 50 % decrease in the difference between involved and uninvolved Free Light Chains levels.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biological Activity of IPH2101 on Killer Immunogloblin Like Receptors (KIR) Occupancy at End of Treatment</title>
        <description>KIR-occupancy is a relative measure of the fraction of cell surface KIR that is occupied by the IPH2101 monoclonal antibody, and hence is unavailable for binding to HLA ligands.</description>
        <time_frame>From the start up to the end of study (15 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: IPH2101 0.2mg/Kg</title>
            <description>every 4 weeks by intravenous route over 1 hour, for 4 or up to 8 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: IPH2101 2mg/kg</title>
            <description>every 4 weeks by intravenous route over 1 hour, for 4 or up to 8 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Biological Activity of IPH2101 on Killer Immunogloblin Like Receptors (KIR) Occupancy at End of Treatment</title>
          <description>KIR-occupancy is a relative measure of the fraction of cell surface KIR that is occupied by the IPH2101 monoclonal antibody, and hence is unavailable for binding to HLA ligands.</description>
          <units>% of occupancy</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.5" lower_limit="33.8" upper_limit="95"/>
                    <measurement group_id="O2" value="96.8" lower_limit="93" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Assessment</title>
        <description>Adverse Events, Serious Adverse Events, physical examination and biological changes.</description>
        <time_frame>from screening visit to the End of Study (at each study visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: IPH2101 0.2mg/Kg</title>
            <description>every 4 weeks by intravenous route over 1 hour, for 4 or up to 8 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: IPH2101 2mg/kg</title>
            <description>every 4 weeks by intravenous route over 1 hour, for 4 or up to 8 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Assessment</title>
          <description>Adverse Events, Serious Adverse Events, physical examination and biological changes.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected from screening visit (date of signature of Inform Consent Form) up to the End of Study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm A: IPH2101 0.2mg/Kg</title>
          <description>every 4 weeks by intravenous route over 1 hour, for 4 or up to 8 cycles.</description>
        </group>
        <group group_id="E2">
          <title>Arm B: IPH2101 2mg/kg</title>
          <description>every 4 weeks by intravenous route over 1 hour, for 4 or up to 8 cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>This serious adverse event was not related to the investigational Medicinal Product</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Michel ATTAL</name_or_title>
      <organization>HOPITAL DE PURPAN Service Hematologie</organization>
      <phone>+33 (0)5.61.77.77.84</phone>
      <email>attal.m@chu-toulouse.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

